Compare HIFS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIFS | FULC |
|---|---|---|
| Founded | 1834 | 2015 |
| Country | United States | United States |
| Employees | 97 | 55 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 535.5M |
| IPO Year | N/A | 2019 |
| Metric | HIFS | FULC |
|---|---|---|
| Price | $289.55 | $7.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 47.0K | ★ 1.0M |
| Earning Date | 01-16-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $209.71 | $2.49 |
| 52 Week High | $338.00 | $15.74 |
| Indicator | HIFS | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 57.36 | 50.95 |
| Support Level | $286.81 | $7.40 |
| Resistance Level | $290.40 | $8.17 |
| Average True Range (ATR) | 9.57 | 0.48 |
| MACD | 2.99 | 0.22 |
| Stochastic Oscillator | 89.44 | 77.87 |
Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.